125,99 €
125,99 €
inkl. MwSt.
Sofort per Download lieferbar
payback
0 °P sammeln
125,99 €
125,99 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
0 °P sammeln
Als Download kaufen
125,99 €
inkl. MwSt.
Sofort per Download lieferbar
payback
0 °P sammeln
Jetzt verschenken
125,99 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
0 °P sammeln
  • Format: PDF

Some drugs which are not aimed at treating heart disease have nevertheless been found to have profound effects on heart muscle. Cardiotoxicity is one of the major forms of toxicity seen in drugs and it accounts for most drug recalls and delays experienced in regulatory approvals.In recent years a number of non-cardiac blockbuster drugs such as terfenadine have been withdrawn from major markets because of cardiotoxicity concerns, while other drugs have either been withdrawn prior to marketing or required labelling changes that significantly restricted their use. In Cardiotoxicity of…mehr

Produktbeschreibung
Some drugs which are not aimed at treating heart disease have nevertheless been found to have profound effects on heart muscle. Cardiotoxicity is one of the major forms of toxicity seen in drugs and it accounts for most drug recalls and delays experienced in regulatory approvals.In recent years a number of non-cardiac blockbuster drugs such as terfenadine have been withdrawn from major markets because of cardiotoxicity concerns, while other drugs have either been withdrawn prior to marketing or required labelling changes that significantly restricted their use. In Cardiotoxicity of Non-Cardiovascular Drugs international experts describe the molecular mechanisms and clinical read-outs of cardiac events induced by a broad variety of noncardiovascular drugs. Particular emphasis is paid to the preclinical screening of drug cardiotoxicity. Topics include: * metabolic targets of cardiotoxicity * regulatory aspects * translating molecular mechanisms into clinical trials * structure-activity relationships in arrhythmias by antihistamines and psychoactive drugs * cardiovascular toxicity of antitumor drugs * cardiovascular toxicities of non-steroidal anti-inflammatory drugs * cardiovascular toxicities of antiretroviral therapies Cardiotoxicity of Non-Cardiovascular Drugs is an essential guide to this important area of drug development. It will find a place on the bookshelves of researchers, regulators and students in medicinal chemistry, drug development, pharmacology, pharmacy and cardiovascular disease.

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Professor Giorgio Minotti, M.D., PhD Professor Minotti is member of the Editorial Board of Cardiovascular Toxicology and Redox Report. He is currently developing an international network of scientists devoted to identifying and disseminating the scientific foundations, regulatory implications and clinical implications of cardiotoxicity induced by a number of noncardiovascular drugs. He has organised and chaired internation symposia on this subject at the EuroTox meetings in 2005 and 2007, and the International Workshop "Anthracycline Cardiotoxicity: Molecular Mechanisms and Clinical Correlates" in Como, October 2006.